The pharmaceutical and bio-technology sectors have been witnessing a strong trend of consolidation through mergers and acquisitions (M&A) over the last few years.
Globally, 166 M&A deals were announced in the pharmaceutical and biotechnology sectors in 2015, up from 137 in 2014, according to The Pharma Letter. Moreover, the number of deals exceeding USD1 billion rose to 30 in 2015 versus 26 in 2014 and 20 in 2013.
Not only are the number of deals increasing, their size is going up too. The average potential deal value in the biotech sector increased to USD320 million in 2015 from USD309 million in 2014, according to a report by E&Y. In 2015, 17 of the alliances in this sector had a total potential value greater than USD1 billion versus 12 in 2014 and only five in 2013.
The reasons behind the rise in the intensity of deal making are not hard to seek. A drop in earnings due to patent expiries on blockbuster drugs, declining R&D productivity and rising pricing pressure are leading to heightened M&A activity. Moreover, US drugmakers are looking at the M&A route to cash in on the benefits of low corporate tax rates in other countries. In the biotech sector, M&As are being driven by the desire of larger biopharma players to secure access to innovative technology platforms.
Why HR is key to successful M&As
Given the mega size of these transactions, there’s more pressure than ever on company managements to ensure that M&As are consummated with as less friction as possible so that the combined entity works as a single unified team to realize the potential benefits of the merger. It is here that the Human Resources (HR) function has a key role to play. HR has the greatest impact in the process of integrating two sets of employees and their daily work processes. One of the potent ways in which HR can ensure a smooth transition to a unified entity post a M&A deal is by focusing on defining a set of desirable cultural attributes and then getting employees to quickly adopt these attributes in their daily behaviour.
This story is from the January 2017 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the January 2017 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
How Tech Innovations Impact Cardiac Care
Cardiac care has seen a transformation over the years with technology playing an important role. Armed with Artificial intelligence (AI) and machine learning (ML), cardiac care providers, with the right technology, have received the right impetus to revolutionise treatment mechanisms. Let us delve into the new technologies which the industry is offering to mankind and decipher the way forward.
Mynvax Offers ‘Warm Vaccine' For COVID-19
Biotech startup Mynvax, incubated at the Indian Institute of Science (IISc) in Bengaluru, has developed heat-tolerant COVID-19 vaccine formulations.
“R&D outsourcing has become a ‘must have' than ‘good-to have' strategy”
Aragen Life Sciences (formerly GVK BIO), a leading contract research and development organisation headquartered in Hyderabad, is marking its transition to a new brand identity in its 20th year. Established in 2001, the company is poised for growth in the outsourced discovery, development, and manufacturing services sector across both large and small molecule platforms with new investments and collaborations. In conversation with BioSpectrum, Manni Kantipudi, Chief Executive Officer, Aragen Life Sciences, Hyderabad reveals more about the company’s recent rebranding and growth plans. Edited excerpts;
Premas Biotech to commercialise VLP vaccine tech against Delta variant
Gurugram-based Premas Biotech has signed a licensing deal with Oravax Medical for the development and commercialisation of its virus-like-particle COVID-19 vaccine technology.
SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future
The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!
Merck launches Pergoveris Pen for fertility treatment in India
Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
Glenmark ties up with SaNOtize to commercialise COVID-19 nasal spray
Mumbai-based Glenmark Pharmaceuticals and Canadian biotech firm SaNOtize Research & Development Corporation
CEPI prioritises Rift Valley fever vax
Sep 01, Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) has signed an implementing partner agreement with Integrum Scientific (US) as part of its ongoing efforts to combat Rift Valley fever (RVF)—one of its priority diseases with epidemic potential.
3D printing moulds healthcare innovations
Pharmaceuticals, bio-medicine, aviation, and automobiles industries have rapidly adopted 3D printing over the years, worldwide, to develop new solutions and prototypes. It is also helping many industries, healthcare, in particular, increase productivity. Despite all its advantages, 3D printing technology is currently posing a number of challenges in the market such as initial costs, limitation to the metals and plastics used for 3D printing, lack of policy standardisation, etc.
